Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Interventions
DRUGOlomorasib
Administered orally.
DRUGPembrolizumab
Administered intravenously (IV).
DRUGDurvalumab
Administered IV.
DRUGPlacebo
Administered orally.
Sponsors
Eli Lilly and Company
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Both Part A and B are randomized, double-blind, placebo-controlled.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological confirmation of NSCLC. * Part A 1. Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible. 2. Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection. * Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy. * Must have disease with evidence of KRAS G12C mutation. * Must have known programmed death-ligand 1 (PD-L1) expression * Must have an ECOG performance status of 0 or 1. * Able to swallow oral medication. * Must have adequate laboratory parameters. * Contraceptive use should be consistent with local regulations for those participating in clinical studies. * Women of childbearing potential must * Have a negative pregnancy test. * Not be breastfeeding during treatment
Exclusion criteria
* Have known, actionable changes in the EGFR or ALK genes. * Have another type of cancer that is progressing or required active treatment within the past 2 years before screening. * Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed. * Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Disease-Free Survival (DFS) by Investigator Assessment | Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years). | DFS by Investigator Assessment |
| Part B: Progression-Free Survival (PFS) by BICR | Randomization to disease progression or death from any cause (Estimated as approximately 3 years). | PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A & B: Overall Survival (OS) | Randomization to disease progression or death from any cause (Estimated as approximately 5 years). | OS |
| Part A & B: Change from baseline in health-related quality of life (HRQoL), measured by European Organization for Research & Treatment of CancerQualityofLifeQuestionnaire-Core 30 (EORTC QLQ-C30) | Randomization through end of treatment (Estimated as approximately 3 years). | Change from baseline in HRQoL, measured by the EORTC QLQ-C30 |
| Part B: PFS by Investigator | Randomization to disease progression or death from any cause (Estimated as approximately 3 years) | PFS per RECIST v1.1 by Investigator |
| Part B: Objective Response Rate (ORR) per RECIST 1.1 by BICR and Investigator | Randomization to disease progression or death from any cause (Estimated as approximately 3 years). | ORR per RECIST 1.1 by BICR and Investigator |
| Part B: Duration of Response (DOR) per RECIST 1.1 by BICR and Investigator | Randomization to disease progression or death from any cause (Estimated as approximately 3 years). | DOR per RECIST 1.1 by BICR and Investigator |
| Part B: Disease Control Rate (DCR) per RECIST 1.1 by BICR and Investigator | Randomization to disease progression or death from any cause (Estimated as approximately 3 years). | DCR per RECIST 1.1 by BICR and Investigator |
| Part B: Time to Response (TTR) per RECIST 1.1 by BICR and Investigator | Randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 3 years). | TTR per RECIST 1.1 by BICR and Investigator |
| Part B: Progression-Free Survival 2 (PFS2) by investigator assessment | Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 3 years).] | PFS2 by investigator assessment |
| Part B: Changes in Non-Small Cell Lung Cancer (NSCLC)-related symptoms, measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) | Randomization through end of treatment (Estimated as approximately 3 years). | Changes in NSCLC-related symptoms, measured by the NSCLC-SAQ |
| Part B: Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ | Randomization through end of treatment (Estimated as approximately 3 years). | Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ |
| Part B: Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ | Randomization through end of treatment (Estimated as approximately 3 years). | Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ |
Countries
Australia, Austria, Belgium, Brazil, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Contacts
CONTACTTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACTPhysicians interested in becoming principal investigators please contact
STUDY_DIRECTORCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Outcome results
None listed